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Angelman syndrome is a neurological disorder whose symptoms
include severe mental retardation, loss of motor coordination, and
sleep disturbances. The disease is caused by a loss of function of
UBE3A, which encodes a HECT-domain ubiquitin ligase. Here, we
generate a Drosophila model for the disease. The results of several
experiments show that the functions of human UBE3A and its fly
counterpart, dube3a, are similar. First, expression of Dube3a is
enriched in the Drosophila nervous system, including mushroom
bodies, the seat of learning and memory. Second, we have gen-
erated dube3a null mutants, and they appear normal externally,
but display abnormal locomotive behavior and circadian rhythms,
and defective long-term memory. Third, flies that overexpress
Dube3a in the nervous system also display locomotion defects,
dependent on the ubiquitin ligase activity. Finally, missense mu-
tations in UBE3A alleles of Angelman syndrome patients alter
amino acid residues conserved in the fly protein, and when intro-
duced into dube3a, behave as loss-of-function mutations. The
simplest model for Angelman syndrome is that in the absence of
UBE3A, particular substrates fail to be ubiquitinated and protea-
somally degraded, accumulate in the brain, and interfere with
brain function. We have generated flies useful for genetic screens
to identify Dube3a substrates. These flies overexpress Dube3a in
the eye or wing and display morphological abnormalities, depen-
dent on the critical catalytic cysteine. We conclude that dube3a
mutants are a valid model for Angelman syndrome, with great
potential for identifying the elusive UBE3A substrates relevant to
the disease.
E6-AP  UBE3A  ubiquitin ligase  mental retardation
Angelman syndrome (AS) is an inherited neurological disorderthat occurs in1/15,000 births and is characterized by mental
retardation, minimal speech, difficulties in motor coordination,
seizures, sleep disorders, and unusual behaviors such as excessive
laughter, excitability, and short attention span (1, 2). AS is caused
by a loss of function of a single gene on chromosome 15 called
UBE3A, which encodes a HECT domain ubiquitin ligase or E3
protein (3, 4). Through covalent interactions with the catalytic
cysteine residue, HECT domain ligases accept ubiquitin from E2
proteins and transfer the ubiquitin to specific substrates (5).
UBE3A was originally called E6-AP because it was initially iden-
tified through its interactions with the viral E6 protein; binding to
E6 subverts the normal substrate specificity of E6-AP to p53, and
p53 degradation leads to cervical cancer (6).
There are four genetic mechanisms known for inheritance of
AS (1). UBE3A is within a region of chromosome 15 that is
paternally imprinted in the hippocampus and in the Purkinje
cells of the brain (7–9). Thus, mutation of the maternally
inherited gene copy underlies all four mechanisms. Most (68%)
cases of AS are because of a deletion in the maternal chromo-
some 15 that includesUBE3A. Mutations in thematernalUBE3A
gene account for another 13% of AS cases, whereas another 6%
are because of imprinting defects and repression of the maternal
UBE3A gene copy. The smallest number (3%) of AS incidences
is caused by paternal uniparental disomy for chromosome 15.
Finally, 10% of people with clear AS symptoms do not fall into
any of the above classes, and the cause of their syndrome is
unknown.
Several mouse models of AS have been generated including
two simple knockouts of the mouse UBE3A homolog on chro-
mosome 7 (10–13). The knockout mutants recapitulate several
aspects of the disease; cerebellar and hippocampal morphology
are normal, but the mice display motor dysfunction, seizures, and
memory defects. Ubiquitination has a variety of effects on
protein function, depending on whether a protein is monoubiq-
uitinated or tagged with a ubiquitin chain depending on how the
ubiquitin chain is linked (14). UBE3A attaches to its substrates
ubiquitin chains that are linked through the K48 residue of the
first ubiquitin and the terminal G76 of the incoming ubiquitin
(15). So-called K48-linked chains usually target substrates for
proteasomal degradation. Thus, the simplest model to explain
why loss of UBE3A activity leads to AS is that in the absence of
the ubiquitin ligase, one or more UBE3A substrates accumulate
in the brain and interfere with brain function. A few UBE3A
substrates have been identified biochemically, but none of them
has been shown to be relevant to AS (16–19).
The Drosophila genome has a UBE3A homolog called dube3a
(20–22), and thus Drosophila genetics could provide a powerful
means to identify Dube3a (and UBE3A) substrates relevant to
AS. Here, we provide compelling evidence that Drosophila
dube3a mutants are indeed a useful AS model.
Results and Discussion
Drosophila UBE3A Homolog dube3a Likely Encodes One Protein Ex-
pressed Throughout Development. The Drosophila gene CG6190,
located at polytene position 68B1 on chromosome 3L (23), has
been identified as dube3a (20–22). There are 14 HECT domain
E3 proteins in Drosophila (23), and the putative Dube3a protein
is clearly the most similar to UBE3A. The fly and human
proteins are similar throughout with the most similarity residing
in their C-terminal HECT domains [supporting information (SI)
Fig. S1]. Using RT-PCR and DNA sequence determination, we
found the predicted dube3a mRNA (23) in embryos, larvae, and
adults (data not shown).
Generation and Molecular Characterization of dube3a Loss-of-Func-
tion Alleles. One mutant dube3a allele, with a P transposable
element inserted in the 5 UTR (23), was available, but dube3a
expression was not obviously disrupted by the P insertion (data
not shown). By mobilizing the P element, we generated three
imprecise excision (deletion) alleles: dube3a80, dube3a6J, and
dube3a15B (Fig. 1A). In addition, we isolated a precise excision
(WT) allele called dube3a6PE that is isogenic with dube3a15B for
the two major autosomes. Homozygotes for each of the deletion
alleles, or trans-heterozygotes of each allele with Df(3L)vin5, a
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chromosome with a deletion that includes dube3a and several
other genes (23), are viable, fertile, and their external morphol-
ogy appears normal.
Two alleles, dube3a6J and dube3a15B, retain the transcription
start (Fig. 1A), and transcripts containing exons downstream of
the deletions were detected by RT-PCR in these mutant flies
(data not shown). In contrast, the transcription start site is within
the deletion in dube3a80, and no dube3a80 transcripts were
detected (data not shown). We used a bacterially produced
full-length Dube3a protein to generate polyclonal anti-Dube3a
antibodies in rats and guinea pigs. Each antibody recognizes a
protein of the expected size (Mr, 107 kDa) in WT third instar
larval eye discs and embryos (data not shown), and neither
full-length nor truncated proteins are detected in any of the
deletion mutants (Fig. 1B; data not shown). The antibody detects
N-terminally truncated Dube3a proteins of Mr 80 kDa or 40
kDa produced in bacteria, that begin at either M353, the first
methionine residue downstream of the dube3a15B deletion break-
point, or M639 (see Fig. S1; data not shown), respectively. Thus,
proteins potentially generated by initiation at downstream start
codons in dube3a6J or dube3a15B mRNAs are unlikely to have
escaped detection. We conclude that the antibodies are specific
for Dube3a, and that the three deletion mutants likely pro-
duce no protein. All of the behavioral studies were performed
with dube3a15B (null mutant) and its isogenic counterpart
dube3a6PE (WT).
Dube3a Expression Is Broad andMainly Cytoplasmic.AS is associated
with loss of UBE3A expression in the developing brain, partic-
ularly in the hippocampal and Purkinje neurons, which are the
seats of memory and motor coordination, respectively. In mice,
UBE3A is broadly expressed early in embryogenesis and later
concentrates in neural tissue (11). Thus, we wanted to determine
whether Dube3a is expressed in the fly central nervous system
during development. Using immunofluorescence, we examined
expression in whole-mount embryos, larval brain and ventral
nerve cord, larval eye discs, and adult brain. Because the
anti-Dube3a signals were robust in embryos only, we generated
flies containing genomic DNA transgenes that express N-
terminally 6xmyc- or GFP-tagged Dube3a proteins from the
dube3a promoter (Fig. 1A).
Embryos were labeled simultaneously with antibodies to
Dube3a and the pan-neural nuclear protein, Elav. We find that
expression of Dube3a is ubiquitous and cytoplasmic, starting
early in embryogenesis and expressed in the developing nervous
system (Fig. 2A and B). The Dube3a antibody is specific in this
Fig. 1. Characterization of WT and mutant dube3a alleles. (A) A diagram of the dube3a genomic region is shown at Upper (not to scale). There is 400 bp
between CG7600 and dube3a, and200 bp between CG6199 and dube3a. Boxes are exons, black indicates coding region, and gray indicates noncoding regions.
The arrows beneath thedube3a exons indicate PCR primers used for transcript detection. Extent of the deletions indube3a alleles is indicated: deletion 6J is1.7
kb, 8O is2.4 kb, and 15B is1.2 kb. Black bars beneath indicate the12.9 kb genomic DNA fragments in each transgene. (B) Shown is a blot of eye disc protein
extracts from third instar larvae. The blots were probed with anti-Dube3a and anti-Tubulin.
Fig. 2. Dube3a protein in Drosophila tissues. Confocal images are shown. (A) A stage 5 embryo. Dube3a accumulates mainly in the cytoplasm and cortically.
(A) Enlargement of part ofA. (B and B) A stage 15 embryo. Dube3a is expressed broadly, including in Elav neural cells. (C) GFPDube3a expression is ubiquitous
and mainly cytoplasmic in third instar larval eye discs. (D) Enlargement of an eye disc expressing 6mDube3a. (E and E) Ventral nerve cord and brain (G and G)
of a third instar larva. Dube3a is expressed ubiquitously in the cytoplasm, with elevated levels in the neuroblasts (which are too young to express Elav) and their
immediate progeny. (F, F, H, and H) Enlargements of regions in (E and E) and (G and G), respectively. NB, neuroblasts. (I–J) show expression in adult brains.
Mushroom bodies (MBs) are marked by nuclear GFP expressed by OK201Y  UAS-nucgfp. (I and J) show different planes.
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assay (Fig. S2).
Next, we examined 6xmyc-tagged Dube3a (6mDube3a) ex-
pression in the larval brain and ventral nerve cord and in adult
brains. Background signal from anti-Myc is insignificant (data
not shown). We colabeled with anti-Elav or coexpressed nuclear
GFP by using UAS-nGFP and one of five different Gal4 drivers
that mark glia, differentiated neurons, neuroblasts, or mushroom
bodies. In the larval brain and nerve cord, 6mDube3a is con-
centrated in the cytoplasm of neuroblasts and their immediate
progeny (Fig. 2 E–H and Fig. S3) and is expressed at much lower
levels in differentiated neurons, glia, and mushroom bodies (Fig.
S3). As in larval brains, 6mDube3a is cytoplasmic and expressed
broadly in the adult brain (Fig. S4). In contrast with larval brains,
6mDube3a is expressed at particularly high levels in the adult
mushroom body (Fig. 2 I and J).
Because we use the eye for the overexpression experiments
below, we wanted to know whether Dube3a is expressed in the
developing eye disc. We find that Dube3a is expressed ubiquitously
in the eye disc and is cytoplasmic (Fig. 2 C and D and Fig. S5).
In summary, similar to the expression of vertebrate UBE3A,
Dube3a protein is mainly cytoplasmic, expressed broadly, and
enriched in adult mushroom bodies.
dube3a Null Mutants Display Abnormal Climbing Behavior. AS pa-
tients display loss of motor coordination, including ataxia and
abnormal gait. Although the dube3amutant flies can walk, climb,
and fly, we noticed that their locomotion behaviors are abnor-
mal. For example, the mutant flies tend to get stuck in the food,
and when knocked to the bottom of a food vial, they take much
longer than theWT flies to begin climbing up. We quantified the
behavior defects by using an established climbing assay (24).
Because motor coordination can be affected by age, WT and
mutant flies of similar ages were compared.
We find that both young and older dube3a mutant flies
perform markedly more poorly than WT in the climbing assay
(Fig. 3A). We asked whether the climbing defect in dube3a
mutants is solely because of loss of dube3a function or whether
effects on expression of the nearby geneCG7600 (Fig. 1A) might
also contribute to the mutant phenotype. We generated trans-
formants with each of two transgenes, one with WT genomic
DNA containing the dube3a gene (gdube3a) and the other with
an identical genomic DNA fragment, except for a missense
mutation in the codon for the critical catalytic cysteine residue
in Dube3a (gdube3aC941A) (Fig. 1A). The analogous mutation in
human UBE3A (UBE3AC820E) destroys the function of the
protein (25), and we show below that the C941A mutation is
unlikely to destabilize Dube3a significantly. Transformant ge-
netic backgrounds were homogenized by rounds of backcrossing
with dube3a6PE. We find that a gdube3a transgene restores WT
climbing ability to the dube3a null f lies, whereas a gdube3aC941A
transgene has no rescuing activity (Fig. 3B). We conclude that
the dube3a null f lies climb poorly because of the dube3a muta-
tion, and that normal locomotion depends on the ubiquitin ligase
activity of Dube3a. We also tested the ability of the dube3a
mutants to initiate flight (26), and we observed no obvious
defect (data not shown). Because Dube3a is expressed widely,
determination of whether the dube3a locomotion behaviors are
because of loss of function in the nervous system requires further
experiments.
Excessive Dube3a Activity in the Nervous System also Results in
Locomotion Defects. We have shown that loss of Dube3a activity
results in loss of climbing ability, presumably because of accu-
mulation of one or more Dube3a substrates. We wondered
whether the motor coordination of flies is also sensitive to
excessive Dube3a ligase activity, and presumably, too little
substrate. To test this possibility, using theGal4/UAS system and
the pan-neural driver elav-gal4, we generated flies that overex-
press dube3a or dube3aC941A in the developing and adult nervous
system. We noticed by casual observation that the flies that
overexpress dube3a, but not dube3aC941A, have locomotion dif-
ficulties similar to the dube3a loss-of-function mutant flies, and
we quantified the effects in two different sets of experiments (see
SI Text and Fig. S6). Because neural overexpression of Dube3a,
but not Dube3aC941A, impairs climbing, we conclude that excess
Dube3a ligase activity in the nervous system impairs locomotion.
Excessive Dube3a Activity During Development Results in Abnormal
Morphology or Lethality. We wondered whether dube3a overex-
pression with strong eye- or wing-specific drivers might generate
morphological defects. We find that overexpression of WT
Dube3a, but not Dube3aC941A, in the eye or wing results in severe
abnormalities, and that ubiquitous overexpression of Dube3a,
but not Dube3aC941A, is lethal (Fig. 4). We also generated several
lines that overexpress N-terminally 3xmyc-tagged versions of
Dube3a and Dube3aC941A, and the results were identical to those
with their untagged counterparts (Fig. S7A). The different
effects of the two proteins are not because of differences in
protein levels, because we found lines where the levels of
3mDube3a and 3mDube3aC941A were similar (Fig. S7B). We
conclude that whereas the absence of Dube3a causes no notice-
able eye or wing defects, nor kills the flies, excessive Dube3a
ligase activity in developing eyes or wings results in aberrant
morphology, and ubiquitous ligase overactivity kills the animals.
To test whether the human gene would affect f ly morphology
similarly to dube3a, we attempted to overexpress human UBE3A
in Drosophila by using the same methods, but we were unable to
do so. This could be because of problems with codon usage or
gene product stability (see SI Text).
Fly dube3a Genes with AS Missense Mutations Act as Loss-of-Function
Mutants. Eight different missense mutant alleles of human
UBE3A that result in loss of function have been identified in
Angelman syndrome patients (27–32). In support of the idea that
the fly and human genes function similarly, all but one of these
mutations are in amino acids conserved between the two species
(Fig. S1). If Drosophila Dube3a functions as human UBE3A
does, we expect that these point mutations would also result in
loss of function of the fly gene. To test this idea, we separately
introduced four of these point mutations into fly 3mdube3a
genes and, by using eye-specific and ubiquitous Gal4 drivers,
tested each mutant gene for function in the overexpression assay
described above. The results are summarized in Fig. S7A. We
Fig. 3. Defective climbing ability because of dube3a loss of function. Results
of climbing tests are shown as averages of 16–18 different trials, each per-
formed on separate populations of20 flies. Error bars are standard error. (A)
At both ages tested, dube3a null mutants perform worse than WT flies. (B) At
both ages tested, a gdube3a transgene (Fig. 1A) rescues the dube3a null
climbing defect to WT, whereas a gdube3aC941A transgene (Fig. 1A) provides
no rescue activity. *, P  0.05
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also assayed Dube3a protein accumulation in several lines, and
representative results are shown in Fig. S7B. We find that two of
the mutant proteins, Dube3aR626C and Dube3aI925K, behave
identically to the catalytically inactive Dube3aC941A protein in
this assay; the mutant proteins accumulate to levels that are
similar to WT protein but do not cause a mutant phenotype.
Dube3aC55Y also behaves likeDube3aC941A in that it fails to cause
a mutant phenotype, but its level of accumulation is lower than
that of Dube3aC941A and WT Dube3a. Finally, Dube3aT447P
showed variable results. Four of six lines, at least one of which
expresses similar levels of protein to WT Dube3a and
Dube3aC941A, result in no phenotypes. However, one line results
in lethality, and one has rough eyes. Dube3aT447P may be a
partially functional protein that can cause a mutant phenotype
only when expressed at higher levels than Dube3a. We conclude
that the fly counterparts of all four of the disease missense alleles
behave as loss-of-function mutations in the fly, probably through
a variety of different mechanisms (33) (see SI Text).
Flies with dube3a Mutations Are Defective in Long-Term Memory
Formation.AS patients suffer severe cognitive impairment.UBE3A
mutant mice may be similarly impaired; they can learn to associate
a tone with a shock (fear conditioning) but have impaired context
dependent long-term memory (LTM) (10). We tested dube3a
mutant flies for defects in olfactory learning and memory; the flies
were trained to associate an odor with a shock and were then tested
for avoidance of the odor (34, 35). As in mice, LTM in Drosophila
requires repeated training (34–36). ‘‘Spaced training,’’ in which 10
training sessions (12 trials in a session) are separated by 15-min rest
intervals, produces LTM that requires protein synthesis and lasts
more than one week (34–36). In contrast, the same 10 training
sessions without the rest intervals, known as ‘‘massed training,’’
induces a different kind of memory that is protein synthesis
independent and decays within 4 d (34–36). One-day memory
performance is usually higher after spaced training than massed
training (34–36). To determine whether dube3a mutant flies have
memory defects, we tested null mutants for 1-d memory after
spaced or massed training, and we found that after spaced training,
their memories were significantly defective when compared with
WT, but similar to WT after massed training (Fig. 5A). The LTM
defect after spaced training cannot be attributed to an inability of
dube3a flies to react to shock or an olfaction deficit because mutant
and WT performed similarly in direct tests of shock reactivity and
olfaction (Fig. 5B). Moreover, the memory deficit is not because of
failure to learn because immediately after a single training session,
null mutants andWT performed similarly (Fig. 5A). The specificity
of the defect to spaced training suggests that, similar to UBE3A
mutant mice, dube3a mutant flies learn as well but cannot form
LTMs as well as WT flies. Because LTM requires particular
transcription factors and protein synthesis (37–39), Dube3a activity
may be involved in regulation of gene expression.
dube3a Null Mutants Have Abnormal Circadian Rhythms. Because
many AS patients suffer sleep disturbance, we asked whether
dube3a mutant flies are defective in rest/activity rhythms. Flies
A B
C D
E F
G H
Fig. 4. Morphological defects in flies that overexpress dube3a in the eye or
wing. Shown are external eyes (A, C, and E) and wings (B, D, and F) of flies that
are WT (A and B) or that overexpress the UAS transgene indicated with the
eye-specific Gal4 driver (GMR-gal4) or the wing-specific driver (MS1096-gal4).
In flies with either the UAS or the Gal4 driver alone, eyes and wings are WT.
(C and D) Eyes are irregular and wing tissue is curly. (E and F) Eyes and wings
are WT. Five different UAS-dube3a lines and two different UAS-dube3aC941A
lines gave the same results as those shown. Ubiquitous overexpression of
Dube3a by using a tubulin-gal4 driver and any of the five UAS-dube3a lines
was lethal, whereas ubiquitous overexpression of Dube3aC941A with either of
two UAS-dube3aC941A lines had no effect. (Scale bar, 200 m in A–F) (G and H)
Tangential sections through WT eyes or eyes overexpressing Dube3a. WT
retinas contain organized hexagonal facets, each with eight photoreceptors
arranged in a trapezoid. Retinal morphology is severely disrupted by Dube3a
overexpression (Scale bar, 20 m in G and H).
Fig. 5. Defective 1-d memory in dube3a mutants specifically after spaced
training. (A) Results of 1-d memory and learning tests are shown. dube3a null
mutants perform worse than WT flies after spaced training but not after
massed training or immediately after a single training session (learning) (8 PI
per genotype; *, P  0.0001). (B) Results of behavioral experiments for
task-relevant olfactory acuity and shock reactivity are shown. No significant
differences were observed between dube3a null mutants and WT (8 PI per
genotype; P  0.61 for 3-octanol (OCT); P  0.98 for 4-methylcyclohexanol
(MCH). Aversion to OCT or MCH was similar in mutant vs. control flies (P 0.55
and P 0.32, respectively; data not shown). There is no significant difference
between dube3a null mutants and WT controls (4 PI per genotype; P 0.78).
Error bars, standard error; PI, performance index; OCT, 3-octanol; MCH,
4-methylcyclohexanol. See Materials and Methods for complete description
of methods and calculation of PI.
12402  www.pnas.orgcgidoi10.1073pnas.0805291105 Wu et al.
were entrained to a 12 h:12 h, light:dark cycle for 3 d before
placing them in locomotor activity monitors that record the
frequency with which a fly crosses an infrared beam passed
through the chamber (40). Activity of the flies was monitored for
12–14 d in constant darkness, which allows for the determination
of free-running circadian rhythms. We tested the behavior of
dube3a null and WT flies, and mutants containing a copy of the
gdube3a transgene (Fig. 1A), and used the data to determine
the periodicity and strength (consolidation) of the rhythm.
Because flies undergo age associated changes in rhythm strength
and period, and the pattern of activity varies with gender (41),
young (4–7 d) and old (18–21 d) flies of each sex were tested
separately. In all three genotypes, we observed periods within
the WT range in rhythmic flies (23.5 h; data not shown).
However, when compared with both controls, a larger fraction
of dube3amutant males were arrhythmic (Table S1), and rhythm
strength was reduced in young males and older flies of both sexes
(Fig. 6). Core proteins of the molecular clock are regulated by
ubiquitin-mediated proteolysis, and two ubiquitin ligases, Slimb
and Jetlag, mediate their degradation (42, 43). More experi-
ments are required to determine whether Dube3a functions
similarly.
dube3a Mutant Flies Are Not Susceptible to Seizures. Because many
AS patients experience seizures, we also subjected dube3a
mutant flies to mechanical stress by vortexing them or heat
shocking them briefly. Subjecting the flies to mechanical or
thermal stress induces paralysis in susceptible flies, a phenom-
enon that is thought to be related to human seizures (44). dube3a
mutant flies of two ages were subjected to each stress, and none
of the flies showed any signs of paralysis (data not shown). The
seizure phenotype is not only variable in AS patients (1, 2) but
also in mouse models (10, 13).
Concluding Remarks. We have generated loss-of-function and
gain-of-function dube3a mutants with great potential for use in
genome-wide, genetic screens to reveal substrates of Dube3a and
UBE3A relevant to AS. Moreover, the fly model provides a
means to test the potential relevance to AS of a Dube3a
substrate; overexpression in the brain of relevant substrates
should result in behavior defects similar to those observed in
dube3a loss-of-function mutations. Genes that pass this test can
then be tested in the mouse model.
Materials and Methods
Drosophila Genetics. The following strains were obtained from the Blooming-
ton Drosophila stock center unless otherwise indicated. dube3aEP(3)3214
(FBti0011388); elav-gal4 (FBti0072910); cha-gal4.7.4 (FBti0024050); repo-gal4
(FBti0018692); OK107-gal4 (FBti0004170); 201Y-gal4 (FBti0002924); l(3)31-
gal4 (FBti0002096; M. Sokolowski, University of Toronto, Mississauga, ON,
Canada); OK6-gal4 (FBti0023258; B. Zhang, University of Oklahoma, Norman,
OK); UAS-nucgfp8 (FBti0012493); GMR-gal4 (FBti0002994); MS1096-gal4
(FBti0002374); tub-gal4 (FBti0012687); Df(3L)vin5 (FBab0002457). A complete
description of the generation and characterization ofdube3amutants is in the
SI Text.
Immunohistochemistry. Embryo immunostaining was performed as described
in ref. 45. Brain immunostaining was as described at: jfly.iam.u-tokyo.ac.jp/
html/manuals/pdf/EStainingItoKei.pdf. Third instar larval eye disk immuno-
staining was as described in ref. 46. A complete list of antibodies and dilutions
is in the SI Text. Tissues were mounted in VectaShield (Vector Laboratories).
Images were acquired with a Leica SP2 AOBS or a TCS-SP confocal microscope
and were manipulated by using Adobe Photoshop.
Molecular Biology. A complete description of standard methods used for
dube3a mRNA analysis, plasmid constructions, protein blotting, and genera-
tion of Dube3a antisera is in the SI Text.
Behavioral Assays. Climbing (24), flight (25, 26), learning and memory (34, 35),
olfaction (47), shock reactivity (48), circadian rhythm (40), and stress tests (49)
were as described. Complete descriptions of each assay are in the SI Text.
Analysis of Eyes andWings.Adult eyes were sectioned and photographed, and
wings were mounted and photographed as described (46, 50).
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